Enhancement of Leucine-lnduced Insulin Secretion by Somatostatin Antiserum Pretreatment

Taniguchi, Hiroya; Hasegawa, Masami; Kobayashi, Tomoyuki; Watanabe, Yoshirô; Murakami, Keiji; Seki, Michiko; Tsutou, Akimitsu; Utsumi, M.; Makimura, Hiroyuki; Sakoda, M; Baba, Shigeaki

doi:10.1055/s-0028-1092675

Cited by 8 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In [S ,201 an increase in insulin release with antisomatostatin serum was also observed but only at a sub-stimulatory or intermediate but not at high glucose concentration. However, the experimental design in [5,20] differed from ours; they preincubated the islets with the antiserum and tested insulin release thereafter without antiserum in the presence of glucose or/and leucine only. Work with precultured rat islets [6] revealed no influence of anti-somatostatin serum on insulin output.…”

Section: Discussionmentioning

confidence: 99%

Studies on the local (paracrine) actions of glucagon, somatostatin and insulin in isolated islets of rat pancreas

Schatz

Kullek

1980

FEBS Letters

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Studies on the local (paracrine) actions of glucagon, somatostatin and insulin in isolated islets of rat pancreas

Schatz

Kullek

1980

FEBS Letters

View full text Add to dashboard Cite

“…This effect has been demonstrated subsequently with very small doses of somatostatin (Lins and Efendic 1979). Studies in vitro have shown that the removal of endogenously released somatostatin by neutralizing antibodies increases insulin release in response to glucose and amino acids (Taniguchi et al 1977;Taniguchi et al 1979). Recent studies in vivo have demonstrated that the removal of circulating somatostatin leads to an increase in postprandial but not basal insulin secretion, suggesting the possibility of an endocrine interaction between insulin and somatostatin (Schusdziarra et al 1980).…”

Section: Insulin -Somatostatin Interrelationshipmentioning

confidence: 99%

Somatostatin - A Regulatory Modulator Connecting Nutrient Entry and Metabolism

Schusdziarra¹

1980

Horm Metab Res

View full text Add to dashboard Cite

“…These data provide evidence that pancreatic somatostatin is a mediator of the suppression of glucagon during hyperglycemia. Diabetes 36:592-96, 1987 I t has been proposed that somatostatin from the 8-cells of the pancreatic islet (1) tonically inhibits pancreatic glucagon and insulin secretion by a paracrine mechanism (1)(2)(3)(4)(5)(6)(7)(8). This hypothesis is based partly on the known inhibitory effect of pharmacologic doses of somatostatin on insulin and glucagon secretion in all species (9)(10)(11) and the anatomical position of the 8-cells between the outer mantle of a-cells and an inner core of p-cells in the rat islet (1,7,8).…”

mentioning

confidence: 99%

Pancreatic Somatostatin is a Mediator of Glucagon Inhibition by Hyperglycemia

Klaff

Taborsky

1987

Diabetes

View full text Add to dashboard Cite

We have previously shown that a nonimmunoreactive analogue of somatostatin, (D-Ala5, D-Trp8)-somatostatin, differentially inhibits pancreatic somatostatin secretion without inhibiting insulin or glucagon secretion. During normoglycemia, suppression of pancreatic somatostatin with this analogue increases glucagon and insulin secretion, suggesting that pancreatic somatostatin tonically inhibits glucagon and insulin secretion by a paracrine mechanism. In our study, we used this analogue to determine whether endogenous pancreatic somatostatin has a role in the inhibition of glucagon secretion by hyperglycemia. The experiments were performed in pentobarbital-anesthetized, laparotomized dogs. To measure the pancreatic output of somatostatin directly, pancreatic venous blood was sampled from the right lobe of the dog pancreas, and the pancreatic blood flow was measured. In the first set of experiments, glucagon secretion was suppressed by a glucose infusion (200 mg/kg bolus and 20 mg X kg-1 X min-1 i.v.) for 3 h. Plasma glucose rose from 102 +/- 6 to 365 +/- 34 mg/dl. Pancreatic insulin output increased 10-fold, pancreatic somatostatin output increased from 1.2 +/- 0.3 to 3.0 +/- 0.8 ng/min, and pancreatic glucagon output was suppressed from 1.4 +/- 0.7 to 0.5 +/- 0.1 ng/min. After 2 h of glucose infusion, an infusion of the analogue (5.5 micrograms/min i.v.) reversed both the stimulation of somatostatin and the suppression of glucagon without significantly changing either the plasma glucose level or the pancreatic insulin output. In a second set of experiments, basal somatostatin output was suppressed by the analogue (5.5 micrograms/min i.v.) for 15 min before the administration of glucose.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Enhancement of Leucine-lnduced Insulin Secretion by Somatostatin Antiserum Pretreatment

Cited by 8 publications

References 0 publications

Studies on the local (paracrine) actions of glucagon, somatostatin and insulin in isolated islets of rat pancreas

Studies on the local (paracrine) actions of glucagon, somatostatin and insulin in isolated islets of rat pancreas

Somatostatin - A Regulatory Modulator Connecting Nutrient Entry and Metabolism

Pancreatic Somatostatin is a Mediator of Glucagon Inhibition by Hyperglycemia

Contact Info

Product

Resources

About